Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands

Thea L. Henry*, Bonnie F.E. de Brouwer, Marjolein M.L. van Keep, Peter J. Blankestijn, Michiel L. Bots, Hendrik Koffijberg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademic

8 Citations (Scopus)
4 Downloads (Pure)


Objectives: Safety and efficacy data for catheter-based renal denervation (RDN) in the treatment of resistant hypertension have been used to estimate the cost-effectiveness of this approach. However, there are no Dutch-specific analyses. This study examined the cost-effectiveness of RDN from the perspective of the healthcare payer in The Netherlands.

Methods: A previously constructed Markov state-transition model was adapted and updated with costs and utilities relevant to the Dutch setting. The cost-effectiveness of RDN was compared with standard of care (SoC) for patients with resistant hypertension. The efficacy of RDN treatment was modeled as a reduction in the risk of cardiovascular events associated with a lower systolic blood pressure (SBP).

Results: Treatment with RDN compared to SoC gave an incremental quality-adjusted life year (QALY) gain of 0.89 at an additional cost of €1315 over a patient’s lifetime, resulting in a base case incremental cost-effectiveness ratio (ICER) of €1474. Deterministic and probabilistic sensitivity analyses (PSA) showed that treatment with RDN therapy was cost-effective at conventional willingness-to-pay thresholds (€10,000–80,000/QALY).

Conclusion: RDN is a cost-effective intervention for patients with resistant hypertension in The Netherlands.
Original languageEnglish
Pages (from-to)76-87
JournalJournal of medical economics
Issue number1
Publication statusPublished - 2015


  • Cost-effectiveness
  • Resistant hypertension
  • Renal sympathetic denervation
  • Prevention
  • Cardiovascular disease
  • n/a OA procedure


Dive into the research topics of 'Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands'. Together they form a unique fingerprint.

Cite this